Initial enthusiasm for anti-Cdk5 treatment for neurodegenerative diseases such as Alzheimer’s disease (AD) led to the generation of a number of lead compounds which showed reasonable potency in vitro. The gene discussed is CDK5; the disease is Alzheimer disease.